Dr. Lal Path Labs

    LALPATHLAB
    Pharma
    ₹1,965.40
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹32,864 Cr

    P/E
    56.36
    Day range
    ₹1,950.00 – ₹1,998.30
    52-week range
    ₹1,272.60 – ₹2,079.00
    Volume
    1.86 L
    Open
    ₹1,972.30
    Prev close
    ₹1,980.20

    Latest results · Q2 FY27(consolidated)Revenue ₹874 Cr+19.6%Profit ₹194 Cr+27.4%Margin 22.2%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 66 / 100

    Factor percentiles

    Value30
    Quality71
    Momentum79
    Low volatility86

    Derived metrics

    Earn. yield
    1.8%
    Graham no.
    ₹361.49
    vs Graham
    -81.6%
    ROE ÷ P/B
    1.8%
    12-1 mom.
    +20.4%
    Return / vol
    0.95
    Magic Formula
    #298
    Piotroski
    3/6
    FCF yield
    1.4%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Dr. Lal Path LabsLALPATHLAB₹32,864 Cr56.3612.2021.8%28.0%32.0%0.08+19.6%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Key metrics

    P/E (TTM)
    55.5
    Price / Book
    11.98
    ROE (FY26)
    21.8%
    ROCE (latest year)
    28%
    Dividend yield
    0.70%

    Moving averages (NSE)

    20-day
    ₹1,939.41
    Price above
    50-day
    ₹1,930.44
    Price above
    200-day
    ₹1,671.96
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +11.1%
    Profit 3Y CAGR
    +28.4%
    Revenue YoY (Sep 2026)
    +19.6%
    Profit YoY (Sep 2026)
    +27.6%
    Operating margin
    32.0%
    Net margin
    22.2%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr250 Cr500 Cr750 Cr1K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%20%40%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • DII
    • FII
    • Public
    • Others
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-500 Cr0 Cr500 Cr1K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr1K Cr2K Cr3K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 19 Dec 2025: earlier bars are per pre-bonus share.

    FY22FY23FY24FY25FY26FY27₹0₹10₹20₹30

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales539545602660597603670731660703798874
    Expenses398401432458443434478506480516550594
    Operating Profit141145170202154169192224179187248280
    OPM %26%27%28%31%26%28%29%31%27%27%31%32%
    Other Income1818212225262825-6243234
    Interest776655557667
    Depreciation363735353636354042454447
    Profit before tax116120150183138153181204124160229260
    Tax %29%28%28%29%29%-1%26%25%26%17%25%26%
    Net Profit82861081319815613415291132170194
    EPS in Rs₹4.87₹5.06₹6.37₹7.73₹5.78₹9.26₹7.90₹8.99₹5.40₹7.84₹10.11₹11.55

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days15

    0 days since Mar 2021

    Inventory Days30

    -9 days since Mar 2021

    Days Payable123

    -9 days since Mar 2021

    Cash Conversion Cycle-79

    -1 days since Mar 2021

    Working Capital Days-29

    -3 days since Mar 2021

    Strengths, risks & growth

    Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]

    Strengths

    • Company is almost debt free.
    • Company has been maintaining a healthy dividend payout of 36.4%

    Risks

    • Stock is trading at 12.2 times its book value
    • The company has delivered a poor sales growth of 11.8% over past five years.

    Compounded Sales Growth

    10 Years
    +13%
    5 Years
    +12%
    3 Years
    +11%
    TTM
    +17%

    Compounded Profit Growth

    10 Years
    +15%
    5 Years
    +12%
    3 Years
    +30%
    TTM
    +13%

    Stock Price CAGR

    10 Years
    +13%
    5 Years
    +2%
    3 Years
    +14%
    1 Year
    +27%

    Return on Equity

    10 Years
    +22%
    5 Years
    +21%
    3 Years
    +22%
    Last Year
    +22%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter53.21%53.21%53.19%52.93%-0.26 pp
    FII20.29%17.18%17.35%18.73%+1.38 pp
    DII19.20%21.37%21.59%21.57%-0.02 pp
    Government0.01%0.01%0.01%0.00%-0.01 pp
    Public6.94%7.88%7.48%6.35%-1.13 pp
    Others0.35%0.34%0.38%0.41%+0.03 pp

    Filed with NSE for Sept 2026: promoters 52.93%, public 46.66%

    Analysts & fund holdings

    73%
    73% recommend buy
    26 analysts cover the stock
    Valuation vs Health Care Providers & Services
    P/E56.4 vs 45.2
    Sector P/B6.05
    Beta0.80

    Who holds the shares, quarter by quarter

    Mutual funds 18.76% (-0.10 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters53.1%
    • Foreign institutions18.8%
    • Mutual funds18.8%
    • Insurance2.5%
    • Other domestic institutions0.4%
    • Retail4.0%
    • Others2.4%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    HDFC Flexi Cap Fund2.23%0.69%-0.03 pp
    UTI Flexi Cap Fund1.39%2.07%+0.06 pp
    Aditya Birla SL Flexi Cap Fund1.35%1.59%+0.23 pp
    SBI Large & Midcap Fund0.75%0.62%+0.04 pp
    Nippon India Small Cap Fund0.74%0.32%+0.01 pp

    Scorecard

    Performance
    Avg
    Valuation
    High
    Growth
    Avg
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026. Adjusted for 1 corporate action.

    Computed

    Risk

    Volatility (1Y)
    28.6%
    Downside volatility
    23.2%
    Worst 5% of days
    2.5%
    Average of that tail
    2.9%
    Max drawdown (1Y)
    24.7%
    Below its peak
    3.2%

    Against the market

    Beta vs Nifty 50
    0.38
    Correlation
    0.18
    Relative strength (3M)
    +0.8%
    ATR (14)
    3.3%

    Return

    Return 1M
    +5.7%
    Return 3M
    +4.7%
    Return 6M
    +19.4%
    Return 1Y
    +27.2%
    vs 200-day average
    +17.6%

    Momentum

    RSI (14)
    52.3
    MACD histogram
    3.14
    Stochastic %K
    48.9
    ADX (14)
    25.2
    +DI / −DI
    20.4 / 14.0
    Money flow index
    47.6

    Participation

    Delivery (20d avg)
    60.2%
    vs its 60-day baseline
    +3.7 pts
    Volume vs 20-day
    -0.7σ
    Close vs day's VWAP
    -0.3%
    52-week position
    91 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    3 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — passed
    Free cash flow
    ₹462 Cr
    FCF yield
    1.4%
    Cash conversion
    1.25
    Accruals ratio
    -0.040
    Net debt
    -₹120 Cr
    Net debt / equity
    -0.04
    EV / sales
    10.79
    Capex intensity
    6.3%
    Revenue CAGR
    28.1%
    Profit CAGR
    15.8%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹48.4 Cr
    42 buys · ₹40.5 Cr
    57 sells · ₹88.8 Cr
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Abhishek Maini
    Designated Person · ESOP
    Buy750₹8.6 L30 Sept 2026
    Abhishek Maini
    Designated Person · Market Sale
    Sell750₹14.7 L30 Sept 2026
    Munender Soperna
    Designated Person · ESOP
    Buy2,100₹20.3 L30 Sept 2026
    Dr. Lal PathLabs Employee Welfare Trust
    Other · ESOP
    Sell4,050₹39.1 L30 Sept 2026
    Mrinal Kapoor
    Designated Person · ESOP
    Buy2,000₹24.5 L25 Sept 2026
    Dr. Lal PathLabs Employee Welfare Trust
    Other · ESOP
    Sell3,000₹36.5 L25 Sept 2026
    Sanjay Kulshreshtha
    Designated Person · ESOP
    Buy1,000₹12.0 L25 Sept 2026
    Sanjay Kulshreshtha
    Designated Person · Market Sale
    Sell1,500₹29.7 L25 Sept 2026
    Mrinal Kapoor
    Designated Person · Market Sale
    Sell2,000₹39.0 L25 Sept 2026
    Jai Prakash Meena
    Designated Person · Market Sale
    Sell4,500₹88.3 L21 Sept 2026
    Sanjay Kulshreshtha
    Designated Person · ESOP
    Buy1,000₹14.3 L21 Sept 2026
    Dr. Lal PathLabs Employee Welfare Trust
    Other · ESOP
    Sell2,350₹25.5 L21 Sept 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹5.00

      Interim Dividend - Rs 5 Per Share

      11 Nov 2026
      ex-date
    • dividend
      ₹5.00

      Interim Dividend - Rs 5 Per Share

      30 Jul 2026
      ex-date
    • dividend
      ₹4.00

      Dividend - Rs 4 Per Share

      25 Jun 2026
      ex-date
    • dividend
      ₹3.50

      Interim Dividend - Rs 3.50 Per Share

      5 Feb 2026
      ex-date
    • bonus
      Not available — not reported in this filing

      Bonus 1:1

      19 Dec 2025
      ex-date
    • dividend
      ₹7.00

      Interim Dividend - Rs 7 Per Share

      7 Nov 2025
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6 Per Share

      6 Aug 2025
      ex-date
    • dividend
      ₹6.00

      Dividend - Rs 6 Per Share

      6 Jun 2025
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6 Per Share

      5 Feb 2025
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6 Per Share

      5 Nov 2024
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6 Per Share

      20 Aug 2024
      ex-date
    • dividend
      ₹6.00

      Dividend - Rs 6 Per Share

      10 Jun 2024
      ex-date
    • dividend
      ₹12.00

      Interim Dividend - Rs 12 Per Share

      13 Feb 2024
      ex-date
    • dividend
      ₹6.00

      Dividend - Rs 6 Per Share

      11 Aug 2023
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6 Per Share

      11 Aug 2023
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6 Per Share

      5 Aug 2022
      ex-date
    • dividend
      ₹6.00

      Annual General Meeting/Dividend - Rs 6 Per Share

      22 Jun 2022
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6 Per Share

      18 Aug 2021
      ex-date
    • dividend
      ₹8.00

      Annual General Meeting/Dividend - Rs 8 Per Share

      20 Jul 2021
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6.00 Per Share

      9 Feb 2021
      ex-date
    • dividend
      ₹6.00

      Interim Dividend - Rs 6 Per Share

      18 Nov 2020
      ex-date

    Company announcements

    Filed with BSE (scrip 539524); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 4 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Dr. Lal Path Labs: common questions

    Answered from the figures on this page.

    Dr. Lal Path Labs last traded at ₹1,965.40 (NSE, as of 18 Nov 2026). The last session moved it down 0.75%.

    Dr. Lal Path Labs is valued at about ₹32,864 crore (NSE, as of 18 Nov 2026).

    Dr. Lal Path Labs trades at a price-to-earnings ratio of 56.36 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Dr. Lal Path Labs has traded between ₹1,272.60 and ₹2,079.00 over the past 52 weeks, to 18 Nov 2026. It is currently 86% of the way up that range.

    Dr. Lal Path Labs (LALPATHLAB) is classified under Pharma on this site's screener.